You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ADCT-901

Showing 1 - 25 of 44
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors Trial in United States (ADCT-901)

Recruiting
  • Advanced Solid Tumors
  • ADCT-901
  • Denver, Colorado
  • +6 more
Jul 18, 2022

Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,

Recruiting
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
  • +4 more
  • ADCT-602
  • Monrovia, California
  • +1 more
Dec 7, 2022

Advanced Solid Tumor Trial in Sutton, Manchester (SL-901)

Recruiting
  • Advanced Solid Tumor
  • Sutton, Surrey, United Kingdom
  • +1 more
May 16, 2022

Diabetic Peripheral Neuropathic Pain Trial (RTA 901, Placebo)

Not yet recruiting
  • Diabetic Peripheral Neuropathic Pain
  • RTA 901
  • Placebo
  • (no location specified)
May 31, 2023

Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Worldwide (Camidanlumab Tesirine)

Active, not recruiting
  • Relapsed Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Camidanlumab Tesirine
  • Scottsdale, Arizona
  • +72 more
Dec 15, 2022

Adverse Events Trial in United States (Irrisept, Standard of Care)

Completed
  • Adverse Events
  • Irrisept
  • Standard of Care
  • Tucson, Arizona
  • +16 more
May 4, 2022

Relapsed DLBCL, Refractory DLBCL Trial in Worldwide (Loncastuximab Tesirine, Rituximab, Gemcitabine)

Recruiting
  • Relapsed Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Loncastuximab Tesirine
  • +3 more
  • La Jolla, California
  • +59 more
Aug 4, 2022

Advanced Solid Tumors Trial in Santa Monica, Oklahoma City (ADCT-601, Gemcitabine)

Recruiting
  • Advanced Solid Tumors
  • Santa Monica, California
  • +9 more
Jan 19, 2023

DLBCL Refractory, Diffuse Large B-cell Lymphoma Recurrent Trial in Worldwide (Loncastuximab tesirine)

Completed
Has Results
  • Diffuse Large B-Cell Lymphoma Refractory
  • Diffuse Large B-cell Lymphoma Recurrent
  • Loncastuximab tesirine
  • Duarte, California
  • +36 more
Aug 18, 2022

Assess Disease Control of Moderate to Severe Atopic Dermatitis

Recruiting
  • Dermatitis Atopic
    • Kuwait, Kuwait
    • +2 more
    May 3, 2022

    Overactive Bladder Trial in Poland, United States (Vibegron)

    Completed
    • Overactive Bladder
    • Huntsville, Alabama
    • +34 more
    Aug 23, 2022

    Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)

    Not yet recruiting
    • Neuroendocrine Carcinomas
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Sep 22, 2023

    Atopic Dermatitis, Eczema, Atopic Trial in France, Réunion (Dupilumab step-down)

    Not yet recruiting
    • Atopic Dermatitis
    • Eczema, Atopic
    • Dupilumab step-down
    • Angers, France
    • +28 more
    Dec 8, 2022

    Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content, Head Neck Cancer Squamous Cell Carcinoma, NSCLC Trial in

    Recruiting
    • Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content
    • +12 more
    • Palo Alto, California
    • +9 more
    Mar 24, 2022

    Acupuncture Therapy, Pneumonectomy, Perioperative Period Trial (Acupuncture and Drug Compound Technology, Routine perioperative

    Not yet recruiting
    • Acupuncture Therapy
    • +3 more
    • Acupuncture and Drug Compound Technology
    • Routine perioperative management
    • (no location specified)
    Jul 7, 2021

    Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Tumor (MDS/MPN) Trial in Durham (ADCT-301)

    Recruiting
    • Acute Myeloid Leukemia (AML)
    • +2 more
    • Durham, North Carolina
      Duke University Health System
    Jan 10, 2022

    DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spain, United States (Loncastuximab Tesirine and Durvalumab)

    Terminated
    Has Results
    • Diffuse Large B-Cell Lymphoma
    • +2 more
    • Loncastuximab Tesirine and Durvalumab
    • Birmingham, Alabama
    • +13 more
    Sep 28, 2021

    Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)

    Recruiting
    • Marginal Zone Lymphoma
    • Loncastuximab tesirine 150 µg/Kg
    • Loncastuximab tesirine 75µg/Kg
    • Miami, Florida
      University of Miami
    Jul 12, 2022

    Pulmonary Arterial Hypertension Trial in Adelaide (AER-901 Solution for Nebulization, Placebo)

    Recruiting
    • Pulmonary Arterial Hypertension
    • AER-901 Solution for Nebulization
    • Placebo
    • Adelaide, South Australia, Australia
      CMAX
    Feb 14, 2022

    Tuberculosis Trial in Dar es Salaam (DAR-901, Sterile saline )

    Completed
    Has Results
    • Tuberculosis
    • DAR-901
    • Sterile saline placebo
    • Dar es Salaam, Tanzania
      Muhimbili University of Health and Allied Sciences
    Apr 17, 2021

    Acute Lymphoblastic Leukemia Trial in United States (ADCT-402)

    Terminated
    Has Results
    • Acute Lymphoblastic Leukemia
    • La Jolla, California
    • +9 more
    Apr 27, 2021

    Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia Trial in Italy, United Kingdom, United States (ADCT-402)

    Completed
    Has Results
    • Non-Hodgkin Lymphoma
    • +8 more
    • La Jolla, California
    • +10 more
    Apr 27, 2021

    Dupilumab in Participants =6 Years With Atopic Dermatitis

    Recruiting
    • Atopic Dermatitis
      • Berlin, Germany
        Investigational Site Number :
      Sep 18, 2023

      Atopic Dermatitis Trial in Taiwan

      Recruiting
      • Atopic Dermatitis
        • Taiwan, Taiwan
          Investigational site number TAIWAN
        Jul 26, 2022

        Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer Trial in Belgium, United States (ADCT-502)

        Terminated
        Has Results
        • Breast Cancer
        • +3 more
        • Palo Alto, California
        • +4 more
        Jan 6, 2021